CN110420315A - Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of - Google Patents
Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of Download PDFInfo
- Publication number
- CN110420315A CN110420315A CN201910802325.4A CN201910802325A CN110420315A CN 110420315 A CN110420315 A CN 110420315A CN 201910802325 A CN201910802325 A CN 201910802325A CN 110420315 A CN110420315 A CN 110420315A
- Authority
- CN
- China
- Prior art keywords
- lycium chinense
- blood
- chinense glycopeptide
- treatment
- glycopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000241872 Lycium chinense Species 0.000 title claims abstract description 48
- 235000015468 Lycium chinense Nutrition 0.000 title claims abstract description 48
- 108010015899 Glycopeptides Proteins 0.000 title claims abstract description 47
- 102000002068 Glycopeptides Human genes 0.000 title claims abstract description 47
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- 239000000725 suspension Substances 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 230000000295 complement effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 15
- 238000005516 engineering process Methods 0.000 claims description 5
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940097043 glucuronic acid Drugs 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 17
- 230000036772 blood pressure Effects 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 10
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 239000008103 glucose Substances 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 12
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 102100038518 Calcitonin Human genes 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 206010038464 renal hypertension Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 235000002710 Ilex cornuta Nutrition 0.000 description 2
- 241001310146 Ilex cornuta Species 0.000 description 2
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- -1 dimethylthiazole hexichol tetrazole Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- VSQUZVLNMULDCY-UHFFFAOYSA-N [O].C1=CC=NC=C1 Chemical compound [O].C1=CC=NC=C1 VSQUZVLNMULDCY-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to drug and field of health care products; application especially specific to Lycium chinense glycopeptide in preparation three high drugs for the treatment of; the purpose of the present invention is to provide Lycium chinense glycopeptides and pharmaceutically acceptable auxiliary material or complementary ingredient to be mixed and made into Chinese medicinal tablet, particle or mix suspension grain, pill, powder or capsule, obtains for treating three high drugs for achieving the purpose that treatment three is high.Find that Lycium chinense glycopeptide can also reduce patch and thrombus simultaneously; activation and protection vascular endothelial cell; improve and increase blood vessel elasticity etc.; to comprehensively and effectively regulate and control blood pressure, blood lipid; keep blood peace and quiet, blood flow is unimpeded, and vessel retraction is free; blood pressure is steady, to effectively prevent a series of generation of cardiovascular and cerebrovascular diseases.For proving that Lycium chinense glycopeptide can be reduced blood pressure by itself pharmacological properties, blood lipid, blood glucose highly prompts its importance in three high treatments, and has significant curative effect.
Description
Technical field
The invention belongs to drug and field of health care products, are related specifically to Lycium chinense glycopeptide answering in preparation three high drugs for the treatment of
With.
Background technique
" three high diseases " refer to hypertension, hyperglycemia (diabetes) and hyperlipidemia.It is " the richness that modern society is derived from
Your disease ", conventional therapy " three high diseases " is all to use Lovastatin, non-promise using medicinal treatment, such as treatment " hyperlipidemia " at present
Bei Te, niacin, Cholestyramine etc.；Although there is many different types of fat-reducing medicaments, side effect is all bigger, and more patients adopt
With the method for diet, to achieve the purpose that control weight, but this treatment method is easy to cause nutrient imbalance, destroys body
The normal function of all organs is extremely worthless treatment method.Ye You medical institutions remove blood using the method for washing blood in vitro
Rouge, although effect is obvious, risk is larger, and easy infection is costly, so patient will not receive this operation easily.
Antihypertensive drugs is even more many kinds of, can substantially be summarized as five major class: diuretics, beta-blocker, calcium channel blocking
Agent (CCB), angiotensin converting enzyme inhibitor (ACEI) and hypertensinⅡreceptorretarder (ARB)；Various depressor
The effect of object and mechanism are different, and effect is multifarious, but basic no any drug can be radically cured, and have
Apparent side effect.Using drug decompression is to damage patient body other internal organs organ functions as cost, as a result, enabling
Impaired human body and organ makes the matter worse, and conventional therapy " hyperglycemia " method is oral hypoglycemic agents or insulin injection, antidiabetic drug
The main function mechanism of object is that stimulation islet cells discharges insulin, reduces hepatic glycogen output, declines blood glucose.All kinds of antidiabetic drugs
Object can continue the function of damage liver, kidney and other organs while glucose-lowering treatment.The toxic side effect of drug is mainly shown as evil
The heart, vomiting, indigestion, liver and kidney cells toxicity, allergic reaction, oligoleukocythemia etc..
Traditional Chinese medicine of the fructus lycii as China, nutritive value, medical care effect and research in the food industry
And application is increasingly extensive.Meanwhile it is strong in view of the comprehensive curative effect of traditional Chinese medicine and have simultaneously letter, just, it is honest and clean, safe, lasting etc. obviously
Advantage, the research about herbal function and clinical application also have become the hot issue of Recent study.Fructus lycii it is main
Ingredient is polysaccharides (LBP), and the Lycium chinense glycopeptide (LBGP) extracted from polysaccharides has been favored by people in recent years,
By the multi-field concern such as medical treatment, food nutrition, health care, beauty, polysaccharides is compared, Lycium chinense glycopeptide eliminates nothing therein
Machine salt and this kind of immunologic incompetence ingredient of various monosaccharide, meanwhile, Lycium chinense glycopeptide has good water solubility, is easy to after edible by people
Body absorbs, bioavilability is high, and the pharmacological action of Lycium chinense glycopeptide is about 20 times of polysaccharides or so；It has been investigated that not
LBGP with dosage has TC, TG effect in blood and liver that reduces, and there is the anti arteriosclerosis of apparent dose-effect relationship LBGP
And to the influence of blood lipid may it is anti-oxidant with it, adjust the factors such as cell calcium homeostasis and apoptosis gene it is related, moreover,
LBGP can be by reducing the content of endothelin level (endothelin, ET) and by increasing blood plasma calcitonin gene
Prevent the generation of hypertension.
Summary of the invention
(1) technical problems to be solved
In view of the foregoing, it is an object to provide Lycium chinense glycopeptide and pharmaceutically acceptable auxiliary material or complementary
Ingredient is mixed and made into Chinese medicinal tablet, particle or mix suspension grain, pill, powder or capsule, obtains using for treating three high drugs
In achieving the purpose that treatment is three high.
(2) technical solution
To solve the technical problem, the present invention provides application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of.
Application of the Lycium chinense glycopeptide provided by the invention in preparation three high drugs for the treatment of can be further arranged to, comprising: institute
It states Lycium chinense glycopeptide and pharmaceutically acceptable auxiliary material or complementary ingredient is mixed and made into various forms of tablets, particle or suspension
Grain, pill, powder or capsule are obtained for treating three high drugs.Wherein, the composition of above-mentioned contained Lycium chinense glycopeptide should meet
Following standard: sugared content >=60%, glucuronic acid content >=5%, protein content 20-33%, the state of the Lycium chinense glycopeptide are pure
The powder of degree >=90%.
Application of the Lycium chinense glycopeptide provided by the invention in preparation three high drugs for the treatment of can be further arranged to, and be that will prepare
Various forms of tablets, particle or mix suspension grain, pill, powder or the capsule obtained is with oral way medication, wherein according to it
Pharmacy unit meter belonging to pharmaceutical technology, the content of Lycium chinense glycopeptide is 10-50mg in per unit.
Lycium chinense glycopeptide provided by the invention can further be set in preparation three high drugs for the treatment of as the application in health food
It is set to, is that various forms of tablets, particle or mix suspension grain, pill, powder or the capsule that will be prepared are used with oral way
Medicine, wherein the content of Lycium chinense glycopeptide is 10-50mg in per unit according to pharmacy unit meter belonging to its pharmaceutical technology.
(3) beneficial effect
Present invention discover that Lycium chinense glycopeptide contained in fructus lycii has centainly hypoglycemic, reducing blood lipid, blood pressure lowering and other effects.
And the high bioactivity of Lycium chinense glycopeptide, make its hundred times stronger than the immunocompetence for clinically commonly taking orally polysaccharide at present.Make
For a kind of fructus lycii glycoprotein, Lycium chinense glycopeptide is important nutritional supplementation source and the cardiovascular and cerebrovascular disease for constituting cells of vascular wall
Blood cleaning machine, to cardiac muscle cell have nutrition building effect, to cardiovascular and cerebrovascular diseases initiation three high diseases, coronary heart disease, blood vessel
The diseases such as atherosis also have significant preventive effect.Lycium chinense glycopeptide can expand blood by adjusting blood pressure CNS inhibition vessel retraction
Pipe, promotes blood circulation, and removes the rubbish in blood, prevents the formation of atheromatous plaque and thrombus.Patch can also be reduced simultaneously
And thrombus, activation and protection vascular endothelial cell, improve and increase blood vessel elasticity etc., to comprehensively and effectively regulate and control blood
Pressure, blood lipid, keep blood peace and quiet, and blood flow is unimpeded, and vessel retraction is free, and blood pressure is steady, to effectively prevent a series of cardiovascular and cerebrovasculars
The generation of disease.
Lycium chinense glycopeptide will not have an impact normal arterial pressure, but by abnormal blood pressure control to normal level, thus
The decompression of Lycium chinense glycopeptide, lipid-loweringing principle are safer, effect is more significant, edible more trust；Lycium chinense glycopeptide can directly and pancreas islet is thin
Born of the same parents combine.On the one hand insulin cell vigor is promoted, the new islet cells of one side self-construction promotes the secretion of insulin,
The control and rehabilitation of diabetes can be realized from the root.And Lycium chinense glycopeptide is pure natural components, without any adverse side effect.
Detailed description of the invention
Fig. 1 is the expression figure of the table 1 in experiment two of the invention；
Fig. 2 is the expression figure of the table 2 in experiment three of the invention.
Specific embodiment
With reference to the accompanying drawing with each experiment, specific embodiments of the present invention will be described in further detail.It tests below
For illustrating the present invention, but it is not intended to limit the scope of the invention.Components, structure, mechanism etc. involved in experiment below, such as
It is then conventional commercial product without specified otherwise.
Experiment one: the cell experiment of Lycium chinense glycopeptide hypoglycemic effect
1. material and method
1.1 material
Experimental subjects is mouse, and wherein mouse NIT-L beta Cell of islet is by Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
It provides；LBGP is provided by fructus lycii research institute, Ningxia academy of agricultural sciences, purity 31.9%, the R-P-MI1640 used in experimentation
Dehydrated medium, trypsase are provided by GIBCO company, the U.S.；The fetal calf serum needed in test is by Hangzhou Chinese holly biology
Engineering Co., Ltd；Alloxan is by this through Suo Laibao Science and Technology Ltd.；Reagent bromination dimethylthiazole hexichol tetrazole (MTT)
Purchased from AMRESCO company；NO, SOD, MDA kit build up biological study institute purchased from Nanjing；Other instruments are provided by laboratory.
1.2 method
Mouse NIT-L1 beta Cell of islet is inoculated into R-P-MI1640 dehydrated medium, environment temperature is 37 DEG C, air
The CO that condition is 5%2, cultivated under conditions of saturated humidity, observe the upgrowth situation of cell at any time using inverted microscope,
It carries out once changing liquid every 2-3d.After cell adherent 80%-90%, row sub-bottle culture, while the cell of logarithmic phase is taken, respectively
It is cultivated using alloxan and LBGP culture solution, test group is set, blank group is both not use, and control group is only
It is cultivated using alloxan culture solution, (low dosage is 10 μ gmL in test group-1；Middle dosage is 20 μ gmL-1；High agent
Amount is 40 μ gmL-1), incubation time is for 24 hours, to leave and take the culture solution of the same period.
1.3 observation index
Using the survival rate of mtt assay indirect determination NIT-L1 pancreaticβ-cell, wherein Detection wavelength is 590nm, and cell is deposited
Motility rate (%)=(OD value experimental group/OD value control group) × 100%；The content for surveying NO, SOD, MDA is in strict accordance on kit
Illustrate carry out.
1.4 statistical method
Collected data are analyzed using 18.0 software of SPSS, wherein measurement data is examined using t, counts money
The comparison of material uses χ2It examines, it is statistically significant as P < 0.05.
2. result
Contacting between 2.1 Lycium chinense glycopeptides and beta Cell of islet survival rate.The survival rate of cellular control unit is substantially less than blank
Group, the survival rate of low, middle and high dose groups cell is substantially higher in model group in test group, and difference has statistical significance (P <
0.05 or P < 0.01)；With the raising of LBGP concentration in culture solution, the survival rate of cell is gradually increasing.
The influence of NO, SOD and MDA content in the beta Cell of islet that 2.2 Lycium chinense glycopeptides induce alloxan；
In blank group and each dosage administration group cell of test group detect NO and MDA content results show obviously will be lower than pair
According to group, and the content of SOD is obviously higher than model group, and difference is statistically significant (P < 0.05)；With Lycium chinense glycopeptide content
Increase, the content of the NO and MDA that detect in cell are in the trend being gradually reduced, and SOD content shows that is gradually risen becomes
Gesture (P < 0.05), specific data see table 1.
The result of NO, SOD and MDA content compares in 1 beta Cell of islet of table
3. discussing
Diabetic is to be damaged that slow then insulin synthesis amount is caused to decline due to the pancreas islet of patient, secretion function occurs
The reason of capable of being affected, beta Cell of islet is the major organs of human body synthesis and excreting insulin, compared to such as other histocytes
By the damage of free radical, alloxan specifically can generate toxic effect to beta Cell of islet, mainly phonetic by four oxygen
Pyridine generates the DNA chain that a large amount of free radical destroys beta Cell of islet, so that beta Cell of islet damage and necrosis, thus insulin synthesis
Amount decline.The mechanism of action of SOD is the disproportionated reaction for being catalyzed ultra-oxygen anion free radical, blocks free radical chain reactions, passes through
The ability that body removes free radical can be reflected by detecting intracellular content.
This experiment, the survival rate of cellular control unit are substantially less than blank group, and difference is obvious, have statistical significance (P <
0.05 or P < 0.01), the results show that alloxan has certain damage to beta Cell of islet；Basic, normal, high dosage in test group
The survival rate of group cell is substantially higher in model group, with the raising of LBGP concentration in culture solution, the survival rate of cell gradually on
It rises, illustrates that Lycium chinense glycopeptide can effectively improve the survival rate of beta Cell of islet.It is examined in blank group and each dosage administration group cell of test group
The content results for surveying NO and MDA, which are shown, will obviously be lower than control group, and the content of SOD is obviously higher than model group, and difference is bright
Aobvious, statistically significant (P < 0.05), with the increase of Lycium chinense glycopeptide content, the content of the NO and MDA that detect in cell are in
The trend being gradually reduced, and SOD content shows the trend (P < 0.05) gradually risen.Conclusion: it is phonetic that Lycium chinense glycopeptide can improve four oxygen
The abduction mechanism of pyridine increases the survival rate of beta Cell of islet, is effectively improved the concentration of NO, SOD, MDA in cell, reaches drop blood
The effect of sugar.
Experiment two: influence of the Lycium chinense glycopeptide to hyperlipidemia rats blood lipid metabolism
1. materials and methods
1.1 research objects: SD rat, SPF grades, male, weight 180-220g is had by Beijing China Fukang biotechnology share
Limit company provides, credit number: SCXK (capital) 2009-0004.Basal feed: corn 20%, soya-bean cake 25%, flour 20%, bran
Skin 20%, fish meal 10%, salt 1%, bone meal 2%, calcium monohydrogen phosphate 1%, multivitamin 1%, high lipid food: basal feed
79%, lard 10%, yolk powder 10%, cholesterol 1%.
1.2 drugs and reagent: LBGP solution is prepared by Ningxia Medical University laboratory；Simvastatin Tablets, Hangzhou Mo Shadong
Pharmaceutical Co. Ltd's production；Lot number: 110183；Sterol, Beijing chemical reagents corporation, lot number: 20100709；Total cholesterol
(TC), triglycerides (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) kit are by Beijing Zhong Shengbei
Control Biotechnology Ltd.'s production.
1.3 instrument and equipments: 55P-72 type low temperature ultracentrifuge, Japanese Hitachi company；7180 type full-automatic biochemicals
Analyzer, Hitachi, Japan；751 type spectrophotometers, Shanghai third analysis instrument factory.
1.4.1 animal packet and model foundation: after taking male SD rat 50, basal feed adaptable fed 1 week, by body
It is randomly divided into 5 groups again, every group 10, respectively blank control group, model group with hyperlipemia, LBGP high and low dose group and the positive
Control group.Modeling method: blank control group feeding basal feed, remaining each group feeding high lipid food, 4 Zhou Houcong blank control groups
5 animals are respectively chosen with model group with hyperlipemia, socket of the eye venous blood sampling, separation serum detects blood lipid level, with model group animal blood
Clear total cholesterol (TC) increases (the P < 0.01 compared with blank control group) and is successfully established for hyperlipemia model.
1.4.2 be administered: after modeling success, LBGP high and low dose group gives LBGP respectively, 3mg/kg and, 1.5mg/kg, sun
Property control group gives Simvastatin 2mg/kg, and blank control group and model group give isometric distilled water.Successive administration 4 weeks, often
Week claims 1 weight, to adjust dosage.
1.4.3 index determining: Rat Fast 12h before experiment terminates, eye socket take blood, and 3000r/min centrifugation separates serum,
It is horizontal using enzymic colorimetric measurement TC, TG, LDL-C and HDL-C.
1.5 statistical methods: experimental data is analyzed using SPSS15.0 statistical software, withIt indicates, compares between group
It is examined compared with t, P < 0.05 is that difference is statistically significant.
2. result
Each group Serum Lipids in Experimental HypercholesterolemicRats is shown in Table 1 (see attached drawing 1).Compared with blank control group, model group with hyperlipemia rat serum
Clear TC, TG, LDL-C are significantly raised (P < 0.01), and HDL-C then significantly reduces (P < 0.01)；With hyperlipemia model
Group compares, and each dosage group Serum TC of LBGP, TG, LDL-C are remarkably decreased (P < 0.05 or P < 0.01), and HDL-C
Then significantly increase (P < 0.05).
Test influence of 3. Lycium chinense glycopeptides to renal hypertensive rat vaso-active substance
1. materials and methods
1.1 modelings, establish 2KIC Renovascular Hypertension Rats
Healthy Male Wistar Rats, weight 140-160g, etherization downlink median abdominal incision, exposure under aseptic condition
The left careful blunt separation of kidney ice goes out left renal artery, and the hair clip shape silver brain clip for being 0.2mm with a swollen outside diameter covers on left renal artery
Cause arteria renalis part narrow, right side kidney remains unchanged, duplication Two-kidney One-clip type hypertension model (two-kidney,
Oneclip renal hypertension model, 2KIC-RH-model).Sham-operation group only separates left renal artery and does not cover silver
Folder, postoperative general muscle are injected penicillin 3 days (4 × 104U, ip, bid), ad lib and water, feed are pure grain fodder.
1.2 grouping
Experimental rat is randomly divided into (1) sham-operation group (c group)；(2) renal hypertension group (RH)；(3) renal hypertension+Chinese holly
Qi glycopeptide group (RH+L group)；(4) Lycium chinense glycopeptide+renal hypertension+Lycium chinense glycopeptide group (L+RH+L group).L+RH+L group is in backed stamper
5 μ l/g stomach-filling of LBGP (the Ningxia pharmaceutical factory of traditional Chinese medicine) 10 days of 10% are used before type, start within second day after reconstructed model the stomach-filling of (3) (4) group
20-25 days, dosage was the same, and (1) (2) group then uses the distilled water stomach-filling of isodose.
Each index is all made ofIt indicates.Two comparison among groups are examined using t, and multicomponent is compared with variance analysis.
2. result
The variation of blood pressure, which is shown in Table 1, LBGP, can prevent 2KIC rat blood pressure from increasing, and administering effect is more significant in advance.
Influence (kPa) of 1 LBGP of table to 2KIC rat blood pressure
*P<0.05；***P<0.001vsC；###P<0.001vsRH
The variation (table 2, see attached drawing 2) of ET, CGRP content in blood plasma and aorta: RH group compared with other groups, blood plasma and
ET content dramatically increases in aorta, and plasma C GRP content is significantly lower than other 3 groups, and CGRP is higher than other in aorta
Group；RH+L, L+RH+L group blood plasma ET are substantially reduced compared with C group and plasma C GRP obviously increases, and ET and CGRP is without bright in aorta
Aobvious variation.Show that ET content increases in renal hypertension blood plasma and aorta, LBGP can be substantially reduced blood plasma ET content, high blood
CGRP discharges obstacle when pressure, and LBGP can prevent this release obstacle.
3. conclusion
LBGP prevents hypertension by reducing blood plasma ET content, and Endothelin ET is the work of vascular endothelial cell secretion
With it is most strong, continue contracting vasoactive peptide at most.From the results, it was seen that ET content in ETRH rat plasma and aortic tissue
It is above control group；And RH+L, L+RH+L blood plasma ET content are not only significantly lower than RH group, also below C group.Prompt ET is synthesized and is released
It puts to increase and has important role in hypertension generation；The rat ET content even substantially less than C group for taking LBGP, shows LBGP
Increase in addition to that can prevent ET content in aorta, can also reduce the generation of ET under basic condition.
It may be the related factor for preventing hypertension from being formed that LBGP, which increases Plasma level of CGRP,.Calcitonin gene (CGRP) is
A kind of biologically active peptide found in recent years in people and in the mammalian body, it is the most strong vasodilator being currently known.Mesh
Preceding research confirms that CGRP activated adenyl cyclase in conjunction with receptor increases intracellular cAMP, plays its biological action.
The mechanism that CGRP reduces blood pressure is the Ant agonism by direct effect to blood vessel and CGRP to ET.
It is above-mentioned it is experimentally confirmed that Lycium chinense glycopeptide can be reduced blood pressure by itself pharmacological properties, blood lipid, blood glucose highly prompts it
Importance in three high treatments, and have significant curative effect.
Finally, it should be noted that the foregoing is only a preferred embodiment of the present invention, it is not intended to restrict the invention,
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features,
All within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in of the invention
Within protection scope.
Claims (4)
1. application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of.
2. application of the Lycium chinense glycopeptide according to claim 1 in preparation three high drugs for the treatment of characterized by comprising
The Lycium chinense glycopeptide and pharmaceutically acceptable auxiliary material or complementary ingredient are mixed and made into various forms of tablets, particle or suspension
Particle, pill, powder or capsule are obtained for treating three high drugs.Wherein, the composition of above-mentioned contained Lycium chinense glycopeptide should expire
The following standard of foot: sugared content >=60%, glucuronic acid content >=5%, protein content 22-38%；The state of the Lycium chinense glycopeptide is
The powder of purity >=90%.
3. the application method of the high drug for the treatment of three prepared in the method according to claim 11, which is characterized in that be
By various forms of tablets, particle or the mix suspension grain, pill, powder or the capsule that prepare with oral way medication, wherein
According to pharmacy unit meter belonging to its pharmaceutical technology, the content of Lycium chinense glycopeptide is 10-50mg in per unit.
4. application method of the high drug for the treatment of three prepared in the method according to claim 11 as health food,
It is characterized in that, being various forms of tablets, particle or the mix suspension grain, pill, powder or the capsule that will prepare with oral
Mode medication, wherein the content of Lycium chinense glycopeptide is 10-50mg in per unit according to pharmacy unit meter belonging to its pharmaceutical technology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910802325.4A CN110420315A (en) | 2019-08-28 | 2019-08-28 | Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910802325.4A CN110420315A (en) | 2019-08-28 | 2019-08-28 | Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110420315A true CN110420315A (en) | 2019-11-08 |
Family
ID=68417926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910802325.4A Pending CN110420315A (en) | 2019-08-28 | 2019-08-28 | Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110420315A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112971127A (en) * | 2021-03-29 | 2021-06-18 | 陕西农产品加工技术研究院 | Medlar glycopeptide auxiliary blood pressure lowering oral liquid and preparation method thereof |
| CN113413455A (en) * | 2021-06-28 | 2021-09-21 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Immunity enhancing composition and application thereof |
| CN113750217A (en) * | 2021-10-26 | 2021-12-07 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide |
| CN114209810A (en) * | 2022-01-06 | 2022-03-22 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease |
| CN114588250A (en) * | 2022-03-18 | 2022-06-07 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating xerophthalmia |
| CN117883549A (en) * | 2024-01-18 | 2024-04-16 | 宁夏医科大学总医院 | Application of lycium barbarum glycopeptide in preparation of product for improving ovarian dysfunction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167887A (en) * | 2007-11-09 | 2008-04-30 | 燕山大学 | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN109628523A (en) * | 2019-01-10 | 2019-04-16 | 华东理工大学 | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and hypoglycemic drug |
-
2019
- 2019-08-28 CN CN201910802325.4A patent/CN110420315A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167887A (en) * | 2007-11-09 | 2008-04-30 | 燕山大学 | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof |
| CN109628523A (en) * | 2019-01-10 | 2019-04-16 | 华东理工大学 | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and hypoglycemic drug |
Non-Patent Citations (1)
| Title |
|---|
| 植物提取物: "枸杞中的关键活性成分—枸杞糖肽", 《百度》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112971127A (en) * | 2021-03-29 | 2021-06-18 | 陕西农产品加工技术研究院 | Medlar glycopeptide auxiliary blood pressure lowering oral liquid and preparation method thereof |
| CN113413455A (en) * | 2021-06-28 | 2021-09-21 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Immunity enhancing composition and application thereof |
| CN113413455B (en) * | 2021-06-28 | 2023-02-14 | 宁夏农林科学院动物科学研究所(宁夏草畜工程技术研究中心) | Immunity enhancing composition and application thereof |
| CN113750217A (en) * | 2021-10-26 | 2021-12-07 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide |
| CN114209810A (en) * | 2022-01-06 | 2022-03-22 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease |
| CN114209810B (en) * | 2022-01-06 | 2023-02-07 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease |
| CN114588250A (en) * | 2022-03-18 | 2022-06-07 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating xerophthalmia |
| CN114588250B (en) * | 2022-03-18 | 2024-01-09 | 宁夏杞肽科技有限公司 | Application of lycium barbarum glycopeptide in preparing medicine for preventing or treating xerophthalmia |
| CN117883549A (en) * | 2024-01-18 | 2024-04-16 | 宁夏医科大学总医院 | Application of lycium barbarum glycopeptide in preparation of product for improving ovarian dysfunction |
| CN117883549B (en) * | 2024-01-18 | 2024-08-16 | 宁夏医科大学总医院 | Application of lycium barbarum glycopeptide in preparation of product for improving ovarian dysfunction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110420315A (en) | Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of | |
| JP4353982B2 (en) | Synergistic composition for the treatment of diabetes | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN103462025A (en) | Health food assisting in reducing blood fat and preparation method and application thereof | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN107580496A (en) | The anti-glycosuria effect of gypenoside 75 | |
| CN104548062B (en) | Drug composition containing glutathione and application of drug composition | |
| CN107537028A (en) | A kind of while auxiliary hyperglycemic and the formula of hypotensive and preparation method thereof | |
| CN103735550B (en) | A kind of pharmaceutical composition and application thereof for the treatment of chronic kidney disease myocardial damage | |
| CN110432500A (en) | A kind of prebiotic compositions and preparation method and purposes containing inulin | |
| CN109381455A (en) | With the composition for adjusting blood glucose, blood lipid and blood pressure function | |
| RU2747985C1 (en) | Solid-phase composition for correction of metabolic disorders in type 2 diabetes mellitus | |
| KR100542809B1 (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1883498A (en) | Compound puerarin for treating cardiovascular and cerebrovascular disease | |
| FR2669823A1 (en) | PHILODENDRON BARK MIXTURE EXTRACT AND CROTON SEEDS, PROCESS FOR PREPARING THE SAME AND DRUG CONTAINING THE SAME. | |
| JP5019708B2 (en) | Composition for the treatment and prevention of diabetes | |
| JP2010168399A (en) | Pharmaceutical for controlling elevation of blood sugar | |
| CN110882286A (en) | Application of wall-removed ganoderma lucidum spore powder | |
| CN100364553C (en) | Natural medicinal composition for preparing diabete drug | |
| TW202034790A (en) | Bitter gourd peptide composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Su Guohui Inventor after: Yu Zhexiong Inventor before: Yu Zhexiong |
|
| CB03 | Change of inventor or designer information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191108 |
|
| WD01 | Invention patent application deemed withdrawn after publication |